Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
Calabresi
F
F
Istituto Regina Elena, Roma, Italy.
Aapro
M
M
Becquart
D
D
Dirix
L
L
Wils
J
J
Ardizzoni
A
A
Gerard
B
B
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000556:secondary; D004341:Drug Evaluation; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use* / Q000633:toxicity; D009943:Organophosphorus Compounds / Q000627:therapeutic use* / Q000633:toxicity; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine